Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Current Leases (2021 - 2025)

Vivos Therapeutics (VVOS) has disclosed Current Leases for 5 consecutive years, with $734000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Current Leases rose 51.34% to $734000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $734000.0, a 51.34% increase, with the full-year FY2024 number at $477000.0, up 0.63% from a year prior.
  • Current Leases was $734000.0 for Q3 2025 at Vivos Therapeutics, up from $654000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $734000.0 in Q3 2025 to a low of $72000.0 in Q4 2021.
  • A 5-year average of $454687.5 and a median of $463500.0 in 2023 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: skyrocketed 481.94% in 2022, then dropped 3.31% in 2025.
  • Vivos Therapeutics' Current Leases stood at $72000.0 in 2021, then surged by 481.94% to $419000.0 in 2022, then increased by 13.13% to $474000.0 in 2023, then rose by 0.63% to $477000.0 in 2024, then skyrocketed by 53.88% to $734000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Current Leases are $734000.0 (Q3 2025), $654000.0 (Q2 2025), and $467000.0 (Q1 2025).